Cost-effectiveness analysis of gemtuzumab ozogamicin for first-line treatment of patients with cd-33 positive acute myeloid leukaemia in spain
Mareque, M. (Pharmacoeconomics and Outcomes Research Iberia (PORIB))
Montesinos, P. (Hospital Universitari i Politècnic La Fe (València))
Font, P. (Hospital General Universitario Gregorio Marañón)
Guinea, J.M. (Organización Sanitaria Integrada Araba)
De La Fuente, Adolfo (Hospital MD Anderson)
Soto, J. (Pfizer)
Oyagüez, Itziar (Pharmacoeconomics and Outcomes Research Iberia (PORIB))
Brockbank, J. (RTI Health Solutions)
Iglesias, Tomás (Pfizer)
Llinares, J. (Pfizer)
Sierra, Jorge (Institut d'Investigació Biomèdica Sant Pau)

Data:	2021
Resum:	Objective: To assess the incremental cost-utility ratio (ICUR) of gemtuzumab ozogamicin (GO) + standard of care (SOC) vs SOC alone for treatment of patients with de novo AML from a Spanish Health Service perspective. Methods: A cohort state-transition model, with 12 health-states, was used to estimate the lifetime accumulated cost and benefits in terms of quality-adjusted-life-years (QALYs) in AML patients with favourable, intermediate, and unknown cytogenetic profiles. Patient profile was defined based on the ALFA-0701 trial. Therapeutic regimens were defined by 5 haematologists. SOC was assumed to be idarubicin and cytarabine, the combination most used in Spain. QALYs were estimated by applying utilities for the time spent by the cohort in each health-state and utility decrements associated with adverse events (AE). Total cost (€,2020) included drug-acquisition, hematologic stem-cell transplantation, disease manage-ment, AE management and end-of-life costs. Unit costs were derived from local databases. All parameters were validated by haematologist. Costs and outcomes were discounted (3%/ year). Results: Higher cost/patient (€177,618 vs €151,434) and greater QALYs (5,70 vs 4,62) were obtained with GO+SOC vs SOC. The ICUR was €24,203/QALY gained. Conclusion: This simulation suggests that GO + SOC could be a cost-effective option for treatment of patients with de novo AML in first line.
Nota:	Altres ajuts: Pfizer Spain.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Cost-effectiveness ; Gemtuzumab ozogamicin ; Acute myeloid leukaemia ; Spain
Publicat a:	ClinicoEconomics and outcomes research, Vol. 13 (2021) , p. 263-277, ISSN 1178-6981

DOI: 10.2147/CEOR.S302097
PMID: 33911887

15 p, 2.9 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats